Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COX-2 inhibition with celecoxib plus first-line chemotherapy in extensive-disease small-cell lung cancer
2012-001877-94Phase 2Completed
- Sponsor
- University Clinic of Pulmonary and Allergic Diseases Golnik
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of celecoxib in small cell lung cancer (SCLC), sponsored by University Clinic of Pulmonary and Allergic Diseases Golnik. Primary endpoint: progression-free survival. Started Sep 2012; status: completed.
02
Drugs
celecoxib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2012-001877-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001877-94.